Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients.

de Fraipont F, Gazzeri S, Cho WC, Eymin B.

Front Genet. 2019 May 7;10:390. doi: 10.3389/fgene.2019.00390. eCollection 2019. Review.

2.

A VEGF-A/SOX2/SRSF2 network controls VEGFR1 pre-mRNA alternative splicing in lung carcinoma cells.

Abou Faycal C, Gazzeri S, Eymin B.

Sci Rep. 2019 Jan 23;9(1):336. doi: 10.1038/s41598-018-36728-y.

3.

[Nuclear EGFR: a new mode of oncogenic signalling in cancer].

Gazzeri S.

Biol Aujourdhui. 2018;212(1-2):27-33. doi: 10.1051/jbio/2018016. Epub 2018 Oct 26. Review. French.

PMID:
30362453
4.

VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop.

Boudria A, Abou Faycal C, Jia T, Gout S, Keramidas M, Didier C, Lemaître N, Manet S, Coll JL, Toffart AC, Moro-Sibilot D, Albiges-Rizo C, Josserand V, Faurobert E, Brambilla C, Brambilla E, Gazzeri S, Eymin B.

Oncogene. 2019 Feb;38(7):1050-1066. doi: 10.1038/s41388-018-0486-7. Epub 2018 Sep 7.

5.

ARF promotes the degradation of the Epidermal Growth Factor Receptor by the lysosome.

Beaumont A, Dayde D, Hatat AS, Barrial C, Perron P, Eymin B, Gazzeri S.

Exp Cell Res. 2018 Sep 15;370(2):264-272. doi: 10.1016/j.yexcr.2018.06.027. Epub 2018 Jun 28.

PMID:
29959911
6.

The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.

Abou Faycal C, Brambilla E, Agorreta J, Lepeltier N, Jacquet T, Lemaître N, Emadali A, Lucas A, Lacal PM, Montuenga L, Pio R, Gazzeri S, Eymin B.

Br J Cancer. 2018 Jun;118(12):1596-1608. doi: 10.1038/s41416-018-0128-4. Epub 2018 May 24.

7.

Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI.

Guerard M, Robin T, Perron P, Hatat AS, David-Boudet L, Vanwonterghem L, Busser B, Coll JL, Lantuejoul S, Eymin B, Hurbin A, Gazzeri S.

Cancer Lett. 2018 Apr 28;420:146-155. doi: 10.1016/j.canlet.2018.01.080. Epub 2018 Feb 6.

PMID:
29421153
8.

Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.

Abou-Fayçal C, Hatat AS, Gazzeri S, Eymin B.

Int J Mol Sci. 2017 Feb 11;18(2). pii: E383. doi: 10.3390/ijms18020383. Review.

9.

Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival.

Dayde D, Guerard M, Perron P, Hatat AS, Barrial C, Eymin B, Gazzeri S.

Oncogene. 2016 Jul 28;35(30):3986-94. doi: 10.1038/onc.2015.480. Epub 2015 Dec 21.

PMID:
26686095
10.

RNA splicing, cell signaling, and response to therapies.

Abou Faycal C, Gazzeri S, Eymin B.

Curr Opin Oncol. 2016 Jan;28(1):58-64. doi: 10.1097/CCO.0000000000000254. Review.

11.

A new function of the splicing factor SRSF2 in the control of E2F1-mediated cell cycle progression in neuroendocrine lung tumors.

Edmond V, Merdzhanova G, Gout S, Brambilla E, Gazzeri S, Eymin B.

Cell Cycle. 2013 Apr 15;12(8):1267-78. doi: 10.4161/cc.24363. Epub 2013 Mar 21.

12.

Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.

Gout S, Brambilla E, Boudria A, Drissi R, Lantuejoul S, Gazzeri S, Eymin B.

PLoS One. 2012;7(10):e46539. doi: 10.1371/journal.pone.0046539. Epub 2012 Oct 10.

13.

p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway.

Ozenne P, Dayde D, Brambilla E, Eymin B, Gazzeri S.

Oncogene. 2013 Feb 21;32(8):1050-8. doi: 10.1038/onc.2012.107. Epub 2012 Mar 26.

PMID:
22450744
14.

Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin.

Van Den Broeck A, Nissou D, Brambilla E, Eymin B, Gazzeri S.

Carcinogenesis. 2012 Feb;33(2):320-5. doi: 10.1093/carcin/bgr292. Epub 2011 Dec 9.

PMID:
22159227
15.

SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines.

Edmond V, Brambilla C, Brambilla E, Gazzeri S, Eymin B.

Cell Cycle. 2011 Jun 15;10(12):1968-77. Epub 2011 Jun 15.

PMID:
21555914
16.

Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin.

Edmond V, Moysan E, Khochbin S, Matthias P, Brambilla C, Brambilla E, Gazzeri S, Eymin B.

EMBO J. 2011 Feb 2;30(3):510-23. doi: 10.1038/emboj.2010.333. Epub 2010 Dec 14.

17.

Sumoylation of ING2 regulates the transcription mediated by Sin3A.

Ythier D, Larrieu D, Binet R, Binda O, Brambilla C, Gazzeri S, Pedeux R.

Oncogene. 2010 Nov 4;29(44):5946-56. doi: 10.1038/onc.2010.325. Epub 2010 Aug 2.

PMID:
20676127
18.

The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.

Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S, Eymin B.

Oncogene. 2010 Sep 30;29(39):5392-403. doi: 10.1038/onc.2010.281. Epub 2010 Jul 19.

PMID:
20639906
19.

The ARF tumor suppressor: structure, functions and status in cancer.

Ozenne P, Eymin B, Brambilla E, Gazzeri S.

Int J Cancer. 2010 Nov 15;127(10):2239-47. doi: 10.1002/ijc.25511. Review.

20.

Telomere maintenance and DNA damage responses during lung carcinogenesis.

Lantuejoul S, Raynaud C, Salameire D, Gazzeri S, Moro-Sibilot D, Soria JC, Brambilla C, Brambilla E.

Clin Cancer Res. 2010 Jun 1;16(11):2979-88. doi: 10.1158/1078-0432.CCR-10-0142. Epub 2010 Apr 19.

21.

Lung cancer: a modified epigenome.

Van Den Broeck A, Ozenne P, Eymin B, Gazzeri S.

Cell Adh Migr. 2010 Jan-Mar;4(1):107-13. Epub 2010 Jan 7. Review.

22.

Role of cell cycle regulators in lung carcinogenesis.

Eymin B, Gazzeri S.

Cell Adh Migr. 2010 Jan-Mar;4(1):114-23. Epub 2010 Jan 16. Review.

23.

Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma.

Ythier D, Brambilla E, Binet R, Nissou D, Vesin A, de Fraipont F, Moro-Sibilot D, Lantuejoul S, Brambilla C, Gazzeri S, Pedeux R.

Lung Cancer. 2010 Aug;69(2):180-6. doi: 10.1016/j.lungcan.2009.11.006. Epub 2009 Dec 4.

PMID:
19962781
24.

A transcriptomic analysis of human centromeric and pericentric sequences in normal and tumor cells.

Eymery A, Horard B, El Atifi-Borel M, Fourel G, Berger F, Vitte AL, Van den Broeck A, Brambilla E, Fournier A, Callanan M, Gazzeri S, Khochbin S, Rousseaux S, Gilson E, Vourc'h C.

Nucleic Acids Res. 2009 Oct;37(19):6340-54. doi: 10.1093/nar/gkp639. Epub 2009 Aug 31.

25.

Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer.

Van Den Broeck A, Brambilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, Eymin B, Khochbin S, Gazzeri S.

Clin Cancer Res. 2008 Nov 15;14(22):7237-45. doi: 10.1158/1078-0432.CCR-08-0869. Epub 2008 Oct 30.

26.

E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35.

Merdzhanova G, Edmond V, De Seranno S, Van den Broeck A, Corcos L, Brambilla C, Brambilla E, Gazzeri S, Eymin B.

Cell Death Differ. 2008 Dec;15(12):1815-23. doi: 10.1038/cdd.2008.135. Epub 2008 Sep 19.

27.

Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels.

Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S, Eymin B.

J Pathol. 2007 Nov;213(3):303-10.

28.

E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors.

Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, Eymin B.

Oncogene. 2007 Oct 18;26(48):6927-36. Epub 2007 Apr 30.

29.

Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation.

Ayrault O, Andrique L, Fauvin D, Eymin B, Gazzeri S, Séité P.

Oncogene. 2006 Dec 7;25(58):7577-86. Epub 2006 Aug 21.

PMID:
16924243
30.

p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress.

Eymin B, Claverie P, Salon C, Leduc C, Col E, Brambilla E, Khochbin S, Gazzeri S.

Mol Cell Biol. 2006 Jun;26(11):4339-50.

31.

p14ARF triggers G2 arrest through ERK-mediated Cdc25C phosphorylation, ubiquitination and proteasomal degradation.

Eymin B, Claverie P, Salon C, Brambilla C, Brambilla E, Gazzeri S.

Cell Cycle. 2006 Apr;5(7):759-65. Epub 2006 Apr 1.

PMID:
16582626
32.

The E-cadherin-beta-catenin complex and its implication in lung cancer progression and prognosis.

Salon C, Lantuejoul S, Eymin B, Gazzeri S, Brambilla C, Brambilla E.

Future Oncol. 2005 Oct;1(5):649-60. Review.

PMID:
16556042
33.

p14ARF promotes RB accumulation through inhibition of its Tip60-dependent acetylation.

Leduc C, Claverie P, Eymin B, Col E, Khochbin S, Brambilla E, Gazzeri S.

Oncogene. 2006 Jul 13;25(30):4147-54. Epub 2006 Feb 27.

PMID:
16501607
34.

E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short).

Salon C, Eymin B, Micheau O, Chaperot L, Plumas J, Brambilla C, Brambilla E, Gazzeri S.

Cell Death Differ. 2006 Feb;13(2):260-72.

35.

HIV-1 Tat targets Tip60 to impair the apoptotic cell response to genotoxic stresses.

Col E, Caron C, Chable-Bessia C, Legube G, Gazzeri S, Komatsu Y, Yoshida M, Benkirane M, Trouche D, Khochbin S.

EMBO J. 2005 Jul 20;24(14):2634-45. Epub 2005 Jul 7.

36.

p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice.

Eymin B, Leduc C, Coll JL, Brambilla E, Gazzeri S.

Oncogene. 2003 Mar 27;22(12):1822-35.

37.

Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.

Eymin B, Gazzeri S, Brambilla C, Brambilla E.

Oncogene. 2002 Apr 18;21(17):2750-61.

38.

Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status.

Chaussade L, Eymin B, Brambilla E, Gazzeri S.

Oncogene. 2001 Oct 4;20(45):6587-96.

39.

No evidence of somatic FGFR3 mutation in various types of carcinoma.

Karoui M, Hofmann-Radvanyi H, Zimmermann U, Couvelard A, Degott C, Faridoni-Laurens L, Ahomadegbe JC, Gazzeri S, Brambilla E, Clerici T, Charbonnier P, Tresallet C, Mitry E, Penna C, Rougier P, Boileau C, Thiery JP, Nordlinger B, Franc B, Radvanyi F.

Oncogene. 2001 Aug 16;20(36):5059-61.

40.

Human ARF binds E2F1 and inhibits its transcriptional activity.

Eymin B, Karayan L, Séité P, Brambilla C, Brambilla E, Larsen CJ, Gazzéri S.

Oncogene. 2001 Mar 1;20(9):1033-41.

41.

Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma.

Eymin B, Gazzeri S, Brambilla C, Brambilla E.

Oncogene. 2001 Mar 29;20(14):1678-87.

42.

Comparison of chromosomal imbalances in neuroendocrine and non-small-cell lung carcinomas.

Michelland S, Gazzeri S, Brambilla E, Robert-Nicoud M.

Cancer Genet Cytogenet. 1999 Oct 1;114(1):22-30.

PMID:
10526531
43.

Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.

Robert C, Bolon I, Gazzeri S, Veyrenc S, Brambilla C, Brambilla E.

Clin Cancer Res. 1999 Aug;5(8):2094-102.

44.

Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.

Brambilla E, Moro D, Gazzeri S, Brambilla C.

J Pathol. 1999 Aug;188(4):351-60.

PMID:
10440744
45.

Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions.

Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S, Brambilla C.

Clin Cancer Res. 1999 Feb;5(2):243-50.

46.

p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck.

Lavieille JP, Gazzeri S, Riva C, Reyt E, Brambilla C, Brambilla E.

Anticancer Res. 1998 Nov-Dec;18(6B):4741-9.

PMID:
9891551
47.

The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer.

Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E.

Cancer Res. 1998 Sep 1;58(17):3926-31.

48.

p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer.

Brambilla E, Gazzeri S, Lantuejoul S, Coll JL, Moro D, Negoescu A, Brambilla C.

Clin Cancer Res. 1998 Jul;4(7):1609-18.

49.

Mechanisms of p16INK4A inactivation in non small-cell lung cancers.

Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E.

Oncogene. 1998 Jan 29;16(4):497-504.

50.

Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors.

Gouyer V, Gazzéri S, Bolon I, Drevet C, Brambilla C, Brambilla E.

Am J Respir Cell Mol Biol. 1998 Feb;18(2):188-96.

PMID:
9476905

Supplemental Content

Loading ...
Support Center